Figure 3.
Occurrence over time of the combined endpoint (fibrosis stage (FS) >/=2, retransplantation and/or liver related death is shown (percent experiencing endpoint shown on y-axis) according to recipient IL28B genotype are shown. The analysis was censored for antiviral therapy. The clinical composite endpoint was significantly associated with recipient and donor, IL28B genotype (p=0.047 and 0.040 for recipient and donor CC vs. TT genotypes respectively).